Allarity Therapeutics, Inc. Stockholders Equity

Quick Answer

Allarity Therapeutics, Inc. reported Stockholders Equity of $9.83 million for fiscal year 2025.

Allarity Therapeutics, Inc. Stockholders Equity — Annual History

Fiscal Year Stockholders Equity YoY Change
2025 $9.83M -16.8%
2024 $11.81M +529.3%
2023 -$2.75M -2334.5%
2022 -$113.0K -100.6%
2021 $18.15M -25.7%
2020 $24.44M +22.0%
2019 $20.04M

Quarterly Stockholders Equity

Quarter Ending Stockholders Equity YoY QoQ
September 30, 2025 $12.01M -7.4% -1.3%
June 30, 2025 $12.17M -38.7% -34.8%
March 31, 2025 $18.67M +388.5% +58.1%
December 31, 2024 $11.81M +529.3% -8.9%
September 30, 2024 $12.96M +483.7% -34.6%
June 30, 2024 $19.84M +2843.4% +406.5%
March 31, 2024 -$6.47M -108.6% -135.2%
December 31, 2023 -$2.75M -2334.5% +18.6%
  • Allarity Therapeutics, Inc. showed a decrease of -16.8% in Stockholders Equity compared to the prior fiscal year.
  • Over the 2019–2025 period, Allarity Therapeutics, Inc.’s stockholders equity has declined by 50.9% (from $20.04 million to $9.83 million).
  • The most recent figure is from Allarity Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 30, 2026.
  • All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.

Last verified:

Leave a Comment